Please use this identifier to cite or link to this item:
|Title:||The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor|
|Authors:||Sharghi-Namini, S. |
|Source:||Sharghi-Namini, S., Fan, H., Sulochana, K.N., Potturi, P., Xiang, W., Chong, Y.-S., Wang, Z., Yang, H., Ge, R. (2008-06-27). The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor. Biochemical and Biophysical Research Communications 371 (2) : 215-219. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bbrc.2008.04.047|
|Abstract:||Angiogenesis is critical for tumour growth and metastasis where factors that regulate this process are potential targets for development of anti-cancer drugs. In this study, we show that the first TSR domain of the extracellular matrix protease ADAMTS5, unlike the second TSR, has anti-angiogenic activities where it inhibits endothelial cell tube formation on Matrigel, reduces cell proliferation and attachment, while promoting cell apoptosis and migration, all in a dose-dependent manner. Furthermore, it influences the architecture of endothelial cells by disrupting actin stress fibres and reducing focal adhesions, likely via suppressing RhoA activation. TSR1 of ADAMTS5 is therefore a novel anti-angiogenic peptide and could serve as a prototype for future development into anti-cancer drugs. © 2008 Elsevier Inc. All rights reserved.|
|Source Title:||Biochemical and Biophysical Research Communications|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 16, 2018
WEB OF SCIENCETM
checked on Dec 11, 2017
checked on Jan 13, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.